DOI: https://dx.doi.org/10.18203/2394-6040.ijcmph20222986
Published: 2022-11-28

COVID-19 and cerebrovascular stroke: a mini review

Debajani Deka, Rupsekhar Deka

Abstract


The novel corona virus has shown accelerated effect on stroke and stroke care. Worlds stroke organization has reported a decline in stroke admission due to use of FAST tool and usage of thrombolysis and thrombectomy. FAST stands for F=facial weakness, A=arm weakness, S=slurred speech T=time to call 911 in USA, 120 in China, 999 in England, 112 in EU. In case of 911, 9=word nine (slurred speech), 1 one arm weakness, 1=one side facial weakness. It has a record that 72% of the confirmed stroke patients had speech disturbance, 62% had facial drooping, and 87% had arm weakness. The most appropriate way to diagnose stroke is motor dysfunction or slurred speech than facial drooping. Articles have been selected from Google scholar, PubMed, PubMed Central, Scopus, Web of Science, Medline, Embase, Scimago, and Publon. Studies on stroke from these articles has shown that speech disturbance has a worse outcome after stroke compared with individuals where speech is unaffected. The incidence of speech disturbance is as high as 84.4% in stroke patients, and a speech disturbance persists at discharge in 75.8% of patients who survived their stroke. Therefore, presence or absence of speech disturbance has predictive value for outcome of a stroke patient. D dimer is very important haematological marker to diagnose Disseminated intra vascular   coagulation (DIC). Again, it is known that sepsis is a common cause of DIC. This biomarker is released when a fibrin blood clot undergo degradation. Tassiopoulos et al mentioned about anticoagulant administration according to D-dimer level can improve respiratory or kidney function in a COVID-19 patient.


Keywords


COVID-19, Stroke, D-dimer, Speech, Facial drooping

Full Text:

PDF

References


Renyu L, Marc F, Anthony R, Jing Z. Speech disturbance plays critical role in stroke recognition during COVID-19 pandemic. CNS Neurosci Ther. 2021;27:267-9.

Ademola SO, Simon AB, Ahmed OI. Acute Ischemic Stroke in COVID-19: Putative Mechanisms, Clinical Characteristics, and Management. Neurol Res Int. 2020;1-7.

Sujan TR, Tanu GC, Shahefábio A, Nascimentoe R, Imrand P, Kanf RB, et al. Cerebrovascular Disease in Patients with COVID-19: A Review of the Literature and Case Series. Case Rep Neurol. 2020;12:199-209.

Wijeratne T, Crewther S. COVID-19 and long-term neurological problems: Challenges ahead with Post-COVID-19 Neurological Syndrome. Aust J Gen Pract. 2021;50.

Kai XC, Sonali P, Stefania DB. Possible affective cognitive cerebellar syndrome in a young patient with COVID-19 CNS vasculopathy and stroke. BMJ Case Rep. 2020;13.

Sherif M, Seham AE, Osama AEH, Azza A, Nashwa A. E-A. incidence and pathophysiologic mechanisms of stroke in the COVID-19 pandemic: the dilemma. Egyptian J Bronchol. 2020;14:31.

Al-Hassany L, Van Den Brink AM. Targeting CGRP in migraine: a matter of choice and dose. Lancet Neurol. 2020;19(9):712-3.

Diener HC, Berlit P, Masjuan J. COVID-19: patients with stroke or risk of stroke. Eur Heart J Suppl. 2020 Dec 23;22:P25-8.

Elkhider H, Ibrahim F, Sharma R, Sheng S, Jasti M, Lotia M, Kapoor N, Onteddu S, Mueed S, Allam H, Nalleballe K. COVID-19 and stroke, a case series and review of literature. Brain Behav Immun Health. 2020;9:100172.

Ramos-Araque ME, Siegler JE, Ribo M, Requena M, López C, de Lera M, et al. Stroke etiologies in patients with COVID-19: the SVIN COVID-19 multinational registry. BMC Neurol. 2021;21(1):43.

Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, Rosser EC, Webb K, Deakin CT. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11(1):6317.

Fraiman P, Godeiro Junior C, Moro E, Cavallieri F, Zedde M. COVID-19 and Cerebrovascular Diseases: A Systematic Review and Perspectives for Stroke Management. Front Neurol. 2020;11:574694.

Vahidy FS, Pan AP, Ahnstedt H, Munshi Y, Choi HA, Tiruneh Y, et al. Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area. PLoS One. 2021;16(1):e0245556.

Nam JH, Park JI, Kim BJ, Kim HT, Lee JH, Lee CH, et al. Clinical impact of blood pressure variability in patients with COVID-19 and hypertension. Blood Press Monit. 2021;26(5):348-56.

Shi L, Wang Y, Wang YD, Duan GC, Yang HY. D-dimer is associated with the risk of mortality in Coronavirus Disease 2019 patients. Eur Rev Med Pharmacol Sci. 2020;24(16):8576-9.

Poudel A, Poudel Y, Adhikari A, Aryal BB, Dangol D, Bajracharya T, et al. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS One. 2021;16(8):e0256744.

Haoting Z, Haizhen C, Chenxi L, Linlin C, Songxin Y, Haolong L, Yongzhe L. Diagnostic Value of D-Dimer in COVID-19: A Meta-Analysis and Meta-Regression. Clinical and Applied Thrombosis/Hemostasis. 2021;27:1-10.

Yumeng Y, Jiatian C, Qingqing W, Qingfeng S, Kai L, Zhe L, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intens Care. 2020;8:49.

Pranav M, Bhagwan D, Nila R, Peter A, McCulloughd. COVID-19-Associated Systemic Thromboembolism: A Case Report and Review of the Literature. Cardiorenal Med. 2020;10:462-9.

Tassiopoulos AK, Mofakham S, Rubano JA, Labropoulos N, Bannazadeh M, Drakos P, et al. D-Dimer-Driven Anticoagulation Reduces Mortality in Intubated COVID-19 Patients: A Cohort Study With a Propensity-Matched Analysis. Front Med (Lausanne). 2021;8:631335.